Cancer
Neoplasm of Uncertain Histogenesis
CI-CAN-00000034Explore in graph →
Non-malignant20,280 active trials259 approved drugs3,813 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00000034Explore in graph →
Clinical trials
91,351 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07843940 | A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) | not yet recruiting | Phase 1 / Phase 2 | 55 | Boehringer IngelheimINDUSTRY | 10 | Sep 30, 2026 | clinicaltrials |
| NCT07848295 | A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) | not yet recruiting | Phase 1 | 112 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 7 | Sep 30, 2026 |
| clinicaltrials |
| NCT07848568 | Testing Safe Doses of Anti-Cancer Medicines, 5-Flurouracil (5-FU) and Tretinoin (ATRA), Added to the Usual Cancer Treatment of Ependymoma | not yet recruiting | Phase 1 / Phase 2 | 70 | Children's Oncology GroupNETWORK | 0 | Sep 30, 2026 | clinicaltrials |
| NCT07849231 | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Mutant Calreticulin Targeted Antibodies in CALR-mutant Myeloproliferative Neoplasms(CLARITY-101) | recruiting | Phase 1 | 250 | Damora TherapeuticsINDUSTRY | 1 | Sep 30, 2026 | clinicaltrials |
| NCT07850921 | REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants | not yet recruiting | Phase 1 / Phase 2 | 192 | Regeneron PharmaceuticalsINDUSTRY | 0 | Sep 30, 2026 | clinicaltrials |
| NCT00591422 | Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas | completed | Phase 1 | 23 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00592163 | Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas | completed | Phase 1 | 20 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT00607711 | Study of Oral Palifosfamide Tris in Solid Tumors | withdrawn | Phase 1 | 0 | Alaunos TherapeuticsINDUSTRY | 0 | Sep 29, 2026 | clinicaltrials |
| NCT01113970 | Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 60 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01242072 | Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies | completed | Phase 1 | 22 | Alaunos TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03187288 | Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS | completed | Phase 1 | 13 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03679650 | Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients | active not recruiting | Phase 1 | 28 | Beth Israel Deaconess Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03802695 | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | recruiting | Phase 1 | 300 | Orca Biosystems, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03837899 | Durvalumab and Tremelimumab for Pediatric Malignancies | active not recruiting | Phase 1 / Phase 2 | 50 | AstraZenecaINDUSTRY | 7 | Sep 29, 2026 | clinicaltrials |
| NCT03842228 | Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations(COD) | active not recruiting | Phase 1 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03897543 | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 10 | Abivax S.A.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04072952 | A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer(mBC) | completed | Phase 1 / Phase 2 | 219 | Arvinas Estrogen Receptor, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04231877 | Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma | active not recruiting | Phase 1 | 56 | University of WashingtonOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04396821 | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 150 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04401020 | First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL | terminated | Phase 1 | 47 | SanofiINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT04495296 | A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04605913 | Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC | active not recruiting | Phase 1 / Phase 2 | 40 | Mayo ClinicOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT04717375 | Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 125 | SanofiINDUSTRY | 4 | Sep 29, 2026 | clinicaltrials |
| NCT05079282 | Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | active not recruiting | Phase 1 | 217 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05273554 | A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05304208 | dENdritic Cell Therapy Combined With SURgEry in Mesothelioma(ENSURE) | recruiting | Phase 1 | 16 | Erasmus Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05322590 | BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma(ASIST) | active not recruiting | Phase 1 / Phase 2 | 195 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05611034 | In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | recruiting | Phase 1 | 10 | University Health Network, TorontoOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05731271 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 111 | Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05741242 | A Phase 1b/2, Multi-center, Single Arm Study to Assess the Safety and Efficacy of Neoantigen Synthetic Long Peptide Vaccines in Patients With Local Or Metastatic Solid Tumors | enrolling by invitation | Phase 1 / Phase 2 | 136 | Jaime Leandro Foundation for Therapeutic Cancer VaccinesOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05803382 | Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05845671 | Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations | active not recruiting | Phase 1 / Phase 2 | 12 | University of Colorado, DenverOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | recruiting | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05891171 | Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25) | active not recruiting | Phase 1 | 40 | Arcus Biosciences, Inc.INDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT05927142 | Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy(DURIPANC) | active not recruiting | Phase 1 / Phase 2 | 43 | Joachim Aerts, MD PhDOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06055075 | A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | Hoffmann-La RocheINDUSTRY | 6 | Sep 29, 2026 | clinicaltrials |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06498648 | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 74 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06667687 | Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 | 21 | AbbVieINDUSTRY | 5 | Sep 29, 2026 | clinicaltrials |
| NCT06763341 | A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06799065 | First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 218 | Accent TherapeuticsINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06865664 | FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma | recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06888921 | A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer(MAIA-ovarian) | recruiting | Phase 1 / Phase 2 | 60 | Compugen LtdINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
| NCT06906471 | A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS | active not recruiting | Phase 1 / Phase 2 | 10 | Antelope Surgical Solutions, IncINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06977711 | Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 1 | 10 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07052305 | NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma | recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07100847 | Periprostatic Neurolysis in Prostate Cancer | active not recruiting | Phase 1 | 21 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07127874 | A Study of PHN-012 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 165 | Pheon TherapeuticsINDUSTRY | 3 | Sep 29, 2026 | clinicaltrials |
Data updated 4 hours agoSource updated Sep 30, 2026source: clinicaltrials